Botwood Nicholas A.J. 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
Syndax (SNDX) CMO Nicholas Botwood Receives Equity Awards
What Happened
Nicholas A.J. Botwood, Syndax Pharmaceuticals’ Head of R&D and Chief Medical Officer, received multiple equity awards on February 4, 2026. The filing shows three grants totaling 204,700 shares: 24,000 RSUs (no cash price), 36,000 performance-based RSUs (no cash price), and a 144,700-share derivative award reported at $20.43 per share (aggregate reported value $2,956,221). These are awards/grants (code A) — not open-market buys or sales.
Key Details
- Transaction date: 2026-02-04; Form 4 filed 2026-02-06 (timely filing).
- Awards: 24,000 RSUs (F1), 36,000 performance-contingent RSUs (F2), 144,700 derivative award shown at $20.43/share = $2,956,221 (F3).
- Total shares awarded: 204,700. RSUs show $0.00 acquisition price on the filing; the derivative is reported with a per-share value.
- Shares owned after transaction: not specified in the filing.
- Footnotes (from the filing):
- F1: 24,000 RSUs vest one-third annually over 3 years.
- F2: 36,000 RSUs vest contingent on pre-established performance metrics and continued service.
- F3: The derivative award vests monthly (1/48th) over four years (typical option-style vesting).
- Transaction code: A = Award/Grant. No 10b5-1, tax-withholding, or late-filing flags were noted.
Context
- These grants represent compensation/retention incentives rather than market purchases; they do not by themselves indicate immediate buying or selling pressure.
- The derivative award appears structured like an option or other equity derivative (vesting schedule in F3), meaning value is realized only as it vests and, if applicable, exercised or converted per plan rules.
- Performance-based RSUs (F2) will only convert to shares if specified goals are met, so the full 36,000 may not ultimately be issued.
Insider Transaction Report
Form 4
Botwood Nicholas A.J.
Head of R&D, CMO
Transactions
- Award
Common Stock
[F1]2026-02-04+24,000→ 59,165 total - Award
Common Stock
[F2]2026-02-04+36,000→ 95,165 total - Award
Stock Options (Right to buy)
[F3]2026-02-04$20.43/sh+144,700$2,956,221→ 144,700 totalExercise: $20.43Exp: 2036-02-04→ Common Stock (144,700 underlying)
Footnotes (3)
- [F1]Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.
- [F2]Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.
- [F3]1/48th of the shares subject to the option shall vest monthly over a four-year period.
Signature
/s/ Michael A. Metzger, Attorney-in-Fact|2026-02-06